Market closedNon-fractional
Avidity Biosciences/RNA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Avidity Biosciences
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Ticker
RNA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
253
Website
www.aviditybiosciences.com
RNA Metrics
BasicAdvanced
$4.1B
Market cap
-
P/E ratio
-$2.97
EPS
0.79
Beta
-
Dividend rate
Price and volume
Market cap
$4.1B
Beta
0.79
Financial strength
Current ratio
12.467
Quick ratio
12.34
Long term debt to equity
0.652
Total debt to equity
1.101
Management effectiveness
Return on assets (TTM)
-20.38%
Return on equity (TTM)
-32.91%
Valuation
Price to revenue (TTM)
275.59
Price to book
4.47
Price to tangible book (TTM)
4.47
Price to free cash flow (TTM)
-20.83
Growth
Revenue change (TTM)
12.50%
Earnings per share change (TTM)
-11.05%
3-year revenue growth
10.15%
3-year earnings per share growth
13.13%
What the Analysts think about RNA
Analyst Ratings
Majority rating from 9 analysts.
RNA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.5M
66.67%
Net income
-$69M
13.91%
Profit margin
-1,965.71%
-31.66%
RNA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.71
-$0.79
-$0.79
-
Expected
-$0.80
-$0.77
-$0.66
-$0.78
-$0.78
Surprise
-17.38%
-7.55%
19.70%
1.84%
-
RNA News
AllArticlesVideos
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Business Wire·1 week ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewsWire·2 weeks ago
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avidity Biosciences stock?
Avidity Biosciences (RNA) has a market cap of $4.1B as of July 04, 2024.
What is the P/E ratio for Avidity Biosciences stock?
The price to earnings (P/E) ratio for Avidity Biosciences (RNA) stock is 0 as of July 04, 2024.
Does Avidity Biosciences stock pay dividends?
No, Avidity Biosciences (RNA) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Avidity Biosciences dividend payment date?
Avidity Biosciences (RNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Avidity Biosciences?
Avidity Biosciences (RNA) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Avidity Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.